Zobrazeno 1 - 10 of 48 pro vyhledávání: '"Aby Buchbinder"'
3
Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia or acute lymphoblastic leukemia
Autor: Xianbin Tian, Aby Buchbinder, Helene Santanastasio, Maria Caterina Putti, Karen Sinclair, Floor Abbink, John Moppett, Carmelo Rizzari, Pamela Kearns, Judith Landman-Parker, Nobuko Hijiya, Brigitte Nelken, Donna Lancaster, C. Michel Zwaan, Robin Foà, Frédéric Millot
Publikováno v: Hijiya, N, Michel Zwaan, C, Rizzari, C, Foà, R, Abbink, F, Lancaster, D, Landman-Parker, J, Millot, F, Moppett, J, Nelken, B, Putti, M C, Tian, X, Sinclair, K, Santanastasio, H, Buchbinder, A & Kearns, P 2020, ' Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia or acute lymphoblastic leukemia ', Clinical Cancer Research, vol. 26, no. 4, pp. 812-820 . https://doi.org/10.1158/1078-0432.CCR-19-0090
Clinical Cancer Research, 26(4), 812-820. American Association for Cancer Research Inc.
Purpose: We investigated nilotinib exposure in pediatric patients with chronic myeloid leukemia (CML) or Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) resistant to, relapsed on, refractory to, or intolerant of previous t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35a4cec703738773a2c5f72af58c0233
https://doi.org/10.1158/1078-0432.ccr-19-0090
Zobrazit plný text záznamu
4
Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor
Autor: Aby Buchbinder, Florence Hourcade-Potelleret, Tycho Heimbach, Handan He, Xianbin Tian, Mary Aghoghovbia, Hefei Zhang
Publikováno v: The Journal of Clinical Pharmacology. 58:1533-1540
Nilotinib, an oral inhibitor of the tyrosine kinase activity of Abelson protein, is approved for the treatment of patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase and patients with CML in chronic phase or accelerated phas
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc9118308e5d05a5e12a324995275424
https://doi.org/10.1002/jcph.1312
Zobrazit plný text záznamu
5
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors
Autor: Rochelle Bagatell, Aby Buchbinder, Robin E. Norris, Suzanne Shusterman, Elizabeth Fox, Jodi A. Muscal, Margaret E. Macy, Lia Gore, Noah Berkowitz
Publikováno v: Pediatric Blood & Cancer. 61:1792-1797
Background EZN-2208 is a water-soluble PEGylated conjugate of the topoisomerase inhibitor SN38, the active metabolite of irinotecan. Compared to irinotecan, EZN-2208 has a prolonged half-life permitting extended exposure to SN38. EZN-2208 has demonst
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3f3e81d8cc4b64ba2d2c961b12867f28
https://doi.org/10.1002/pbc.25105
Zobrazit plný text záznamu
6
Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer
Autor: Aby Buchbinder, Christopher R. Garrett, Theresa Ryan, Einat Shacham-Shmueli, Tanios Bekaii-Saab, Sally Clive, George A. Fisher, Petr Kavan, Richard M. Goldberg
Publikováno v: Cancer. 119:4223-4230
BACKGROUND Irinotecan is cytotoxic in patients with advanced colorectal cancer (CRC). SN-38 (10-hydroxy-7-ethyl-camptothecin) is the active metabolite of irinotecan. Attachment of polyethylene glycol (PEG) polymer chains (pegylation) to SN-38 (EZN-22
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ea228a204a1d5718e5b134d408b54666
https://doi.org/10.1002/cncr.28358
Zobrazit plný text záznamu
7
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer
Autor: Saik Urien, Sanaa Tahiri, Aby Buchbinder, Tanios Bekaii-Saab, Muralidhar Beeram, Keyvan Rezai, Kyriakos P. Papadopoulos, Amita Patnaik, François Lokiec, Anthony W. Tolcher, Larry J. Schaaf
Publikováno v: Cancer Chemotherapy and Pharmacology. 71:1499-1506
This study evaluated the tolerability, pharmacokinetics, and preliminary antitumor activity of EZN-2208, a water-soluble poly(ethylene) glycol conjugate of SN38.Patients with advanced malignancies were enrolled in dose-escalating cohorts (3 + 3 desig
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88d09ade7e7152c5b1dfd45d8dba8259
https://doi.org/10.1007/s00280-013-2149-2
Zobrazit plný text záznamu
8
Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies
Autor: Sridhar Mani, David S. Hong, Keyvan Rezai, Mohammed Ghalib, Siqing Fu, Sonia K. Morgan-Linnell, Razelle Kurzrock, Aby Buchbinder, François Lokiec, Mary F. Mulcahy, Sanjay Goel, Saik Urien, Imran Chaudhary, Jennifer J. Wheler
Publikováno v: Cancer. 118:6144-6151
BACKGROUND: EZN-2208 is a water-soluble, polyethylene glycol drug conjugate of SN38, which is the active moiety of irinotecan. In this study, the authors evaluated the tolerability, pharmacokinetics (PK), and activity of EZN-2208 in adult patients wi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9a2d54b1c3d6513e180238c26c72dbf7
https://doi.org/10.1002/cncr.27647
Zobrazit plný text záznamu
9
P3-16-18: Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients with Previously Treated Metastatic Breast Cancer
Autor: MA Steinberg, Frankie A. Holmes, Noah Berkowitz, Joyce A. O'Shaughnessy, Aby Buchbinder, Heetae Kim, Paul Richards, CR Osborne, Svetislava J. Vukelja, Darren M. Kocs
Publikováno v: Cancer Research. 71:P3-16
Background EZN-2208 is a water-soluble PEGylated conjugate of SN38 that results in parenteral delivery, increased solubility, higher exposure, and longer apparent half-life of SN38, as well as more profound deoxyribonucleic acid (DNA) damage and inhi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1580636add697670861ee41af39db013
https://doi.org/10.1158/0008-5472.sabcs11-p3-16-18
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje